外科理论与实践2012，Vol.17Issue(2)：130-134,5.DOI:10.3969/j.issn.1007-1096.2012.02.010
埃罗替尼和塞来昔布抑制胆管癌生长和血管生成
Combination of erlotinib with celecoxib inhibits tumor growth and angiogenesis of cholangiocarcinoma
摘要
Abstract
Objective Aberrant activation of the epidermal growth factor receptor and COX-2 is frequently observed in cholangiocarcinoma. This study aims to evaluate the inhibitory effect on the growth of cholangiocarcinoma by simultaneously blocking both EGFR and COX-2. Methods A combination of EGFR-selective tyrosine kinase inhibitor (EGFR TKI) erlotinib with a COX-2 inhibitor (C0X-2I) celecoxib was studied for its effects on the growth of transplanted human cholangiocarcinoma in nude mice. Results Tumor growth was significantly inhibited by combined treatment compared with the control (P<0.01), celecoxib (P<0.01), or erlotinib (P<0.05) treatment. The synergistic effect of these two agents in combination was also associated with down-regulation of p-MAPK and reduction of vascular endothelial growth factor and Ki-67 expression. Apoptosis was also increased as indicated. Conclusions The combined treatment can inhibit tumor progression in vivo cooperatively by both antiangiogenic effect and direct effects on tumor cell proliferation and apoptosis. This combination regimen may provide a promising strategy for cancer therapy.关键词
表皮生长因子受体/环氧合酶-2/靶向治疗/胆管癌Key words
Epidermal growth factor receptor/ COX-2/ Targeted therapy/ Cholangiocarcinoma分类
医药卫生引用本文复制引用
李勤裕,施敏敏,彭承宏..埃罗替尼和塞来昔布抑制胆管癌生长和血管生成[J].外科理论与实践,2012,17(2):130-134,5.基金项目
上海市科委医学导引项目(08411968000) （08411968000）
